Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins

Journal of Virology

Volumn 70, Issue 7, 1996, Pages 4871-4876

  Ulich, Catherine ^a   Harrich, David ^a   Estes, Pila ^b   Gaynor, Richard B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; MUTANT PROTEIN; REGULATOR PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; FLOW CYTOMETRY; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIROGENESIS; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029934083     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.7.4871-4876.1996     Document Type: Article

References (51)

1. Aguilar-Cordova, E., J. Chinen, L. A. Donehower, J. W. Harper, A. P. Rice, J. S. Butel, and J. W. Belmont. 1995. Inhibition of HIV-1 by a double transdominanl fusion gene. Gene Ther. 2:181-186.
2. Ahmed, V. F., S. M. Hanly, M. H. Malim, B. R. Cullen, and W. C. Greene. 1990. Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev. 4:1014-1022.
3. Bahner, I., C. Zhou, X.-J. Yu, Q.-L. Hao, J. C. Guatelli, and D. B. Kohn. 1993. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 67:3199-3207.
4. Baltimore, D. 1988. Intracellular immunization. Nature (London) 335:395-396.
5. Bevec, D., M. Dobrovnik, J. Hauber, and E. Bohnlein. 1992. Inhibition of human immunodeficiency virus type 1 replication in human T-cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad. Sci. USA 89:9870-9874.
6. Bogerd, H., and W. C. Greene. 1993. Dominant negative mutants of human T-cell leukemia virus type 1 Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo. J. Virol. 67:2496-2502.
7. Bogerd, H. P., R. A. Fridell, S. Madore, and B. R. Cullen. 1995. Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell 82:485-494.
8. Calnan, B. J., S. Biancalana, D. Hudson, and A. D. Frankel. 1991. Analysis of arginine-rich peptiues from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev. 5:201-210.
9. Carroll, R., L. Martarano, and D. Derse. 1991. Identification of lentivirus Tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras. J. Virol. 65:3460-3467.
10. Dayton, A. I., J. G. Sodroski, C. A. Rosen, W. C. Goh, and W. A. Haseltine. 1986. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941-947.
11. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh, and M. A. Skinner. 1990. HIV-1 Tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 9:4145-4153.
12. Echetebu, C. O., H. Rhim, C. H. Herrmann, and A. P. Rice. 1994. Construction and characterization of a potent HIV-2 Tat transdominant mutant protein. J. Acquired Immune Defic. Syndr. 7:655-664.
13. Fauci, A. S. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011-1018.
14. Feinberg, M. B., R. F. Jarrett, A. Aldovini, R. C. Gallo, and F. Wong-Staal. 1986. HTLV-III expression and production involve complex regulation at the levels of splicing and translation of RNA. Cell 46:807-817.
15. Fisher, A. G., M. B. Feinberg, S. F. Josephs, M. E. Harper, L. M. Marselle, G. Reyes, M. A. Gonda, A. Aldovini, C. Debouk, R. C. Gallo, and F. Wong-Staal. 1986. The trans-activator gene of HTLV-III is essential for virus replication. Nature (London) 320:367-371.
16. Fisher, A. G., J. Huber, W. C. Boeiens, I. W. Mattaj, and R. Luhrmann. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82:475-483.
17. Garcia, J. A., D. Harrich, L. Pearson, R. Mitsuyasu, and R. B. Gaynor. 1988. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J. 7:3143-3147.
18. Gougeon, M.-L., and L. Montagnier. 1943. Apoptosis in AIDS. Science 260:1269-1270.
19. Herrmann, C. H., and A. P. Rice. 1995. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1612-1620.
20. Hope, T. J., N. P. Klein, M. E. Elder, and T. G. Parslow. 1992. Transdominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes. J. Virol. 66:1849-1855.
21. Hope, T. J., D. McDonald, X. Huang, J. Low, and T. G. Parslow. 1990. Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: essential residues near the amino terminus. J. Virol. 64:5360-5366.
22. Kim, S. Y., R. Byrn, J. Groopman, and D. Baltimore. 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63:3708-3713.
23. Kubota, S., R. Furuta, M. Maki, and M. Hatanaka. 1992. Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev. J. Virol. 66:2510-2513.
24. Li, C. J., D. J. Friendman, C. Wang, V. Meteleve, and A. B. Pardee. 1995. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268:429-431.
25. Lisziewicz, J., D. Sun, B. Trapnell, M. Thomson, H.-K. Chang, B. Ensoli, and B. Peng. 1995. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J. Virol. 69:206-212.
26. Liu, J., C. Woffendin, Y. Zhi-yong, and G. J. Nabel. 1994. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T-cells. Gene Ther. 1:32-37.
27. Lo, K. M. S., M. A. Biasolo, G. Dehni, G. Palu, and W. A. Haseltine. 1992. Inhibition of replication of HIV-1 by retroviral vectors expressing tot-antisense and anti-tot ribozyme RNA. Virology 190:176-183.
28. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
29. Malim, M. H., and B. R. Cullen. 1991. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 65:241-248.
30. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T-cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
31. Malim, M. H., J. Hauber, S. Y. Le, J. V. Maizel, and B. R. Cullen. 1989 The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (London) 338:254-257.
32. Malim, M. H., D. F. McCarn, L. S. Tiley, and B. R. Cullen. 1991. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 65:4248-4254.
33. Malim, M. H., L. S. Tiley, D. F. McCarn, J. R. Rusche, J. Hauber, and B. R. Cullen. 1990. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 60:675-683.
34. Meyer, B. E., and M. H. Malim. 1994. The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev. 8:1538-1547.
35. Mhashilkar, A. M., J. Bagley, S. Y. Chen, A. M. Szilvay, D. G. Heiland, and W. A. Marasco. 1995. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14:1542-1551.
36. Modesti, N., J. Garcia, C. Debouck, M. Peterlin, and R. Gaynor. 1991. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol. 3:759-768.
37. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
38. Nabel, G. J. 1994. Gene therapy approaches to AIDS. AIDS 8:561-569.
39. Olsen, H. S., A. W. Cockrane, P. J. Dillon, C. M. Nalin, and C. A. Rosen. 1990. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev. 4:1357-1364.
40. Olsen, H. S., N. Peter, A. W. Cochrane, and C. A. Rosen. 1990. Secondary structure is the major determinant for interaction of HIV Rev protein with RNA. Science 247:845-848.
41. Pearson, L., J. Garcia, F. Wu, N. Modesti, J. Nelson, and R. Gaynor. 1990. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc. Natl. Acad. Sci. USA 87:5079-5083.
42. Popovic, M., M. G. Sarnagadheran, E. Recid, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
43. Roy, S., H. Delling, C.-H. Chen, C. A. Rosen, and N. Sonenberg. 1990. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev. 4:1365-1373.
44. Ruben, S., A. Perkins, R. Purcell, K. Joung, R. Sia, R. Burghoff, W. A. Haseltine, and C. A. Rosen. 1989. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol. 63:1-8.
45. Sadaie, M. R., T. Renter, and F. Wong-Staal. 1988. Site-directed mutagenesis of two trans-regulatory genes (tat-III, trs) of HIV-1. Science 239:910-913.
46. Siomi, H., H. Shida, M. Maki, and M. Hatanaka. 1990. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol. 54:1803-1807.
47. Sodroski, J. G., W. C. Rosen, C. Dayton, A. Terwilliger, and W. Haseltine. 1986. A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature (London) 321:412-417.
48. Trono, D., M. Feinberg, and D. Baltimore. 1989. HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59:113-120.
49. Vandendriessche, T., M. K. L. Chuah, L. Chiang, H.-K. Chang, B. Ensoli, and R. A. Morgan. 1995. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD44 T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 69:4045-4052.
50. Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K.-M. Debatin, and P. H. Krammer. 1995. Sensitization of T-cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (London) 375:497-500.
51. Zapp, M. L., T. J. Hope, T. G. Parslow, and M. R. Green. 1991. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc. Natl. Acad. Sci. USA 88:7734-7738.